Dabigatran Etexilate Mesylate

DRUG4 trials

Sponsors

Vanderbilt University Medical Center, Janssen Research & Development, LLC, Mayo Clinic, Daiichi Sankyo Co., Ltd.

Conditions

Acute PancreatitisAtrial FibrillationAtrial FlutterDrug-drug InteractionHealthyHealthy SubjectsPharmacokineticsQuizartinib

Early Phase 1

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

CompletedNCT04459585

Daiichi Sankyo Co., Ltd.Drug-drug Interaction, Healthy Subjects, Pharmacokinetics +1

Start: 2020-08-28End: 2020-10-20Updated: 2021-07-09

Phase 1

A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

CompletedNCT02945020

Janssen Research & Development, LLCHealthy

Start: 2016-11-10End: 2017-01-20Updated: 2025-02-03

Treating Acute Pancreatitis With Dabigatran, a Pilot Study

TerminatedNCT03807856

Mayo ClinicAcute Pancreatitis

Start: 2019-06-24End: 2020-07-23Updated: 2022-09-01

Phase 4

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

CompletedNCT01976507

Vanderbilt University Medical CenterAtrial Fibrillation, Atrial Flutter

Start: 2013-10-31End: 2016-12-31Updated: 2017-09-12